Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · 10% owner | June 18, 2021 | June 22, 2021 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 09, 2022 | June 10, 2022 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director · 10% owner | June 28, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.55 · Expires 2031-06-17 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.
CRISPR Therapeutics AG
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.70 · Expires 2032-06-09 | Direct | 12,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 12,000 · Balance 12,000 F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.
Monte Rosa Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital VI, L.P. | 6,799,115 |
Reported balance
After 2021-06-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-28 · Conversion · Acquired 6,515,869 · Balance 6,799,115 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage I, L.P. | 2,097,938 |
Last balance in matching sequence
After 2021-06-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-06-28 · Conversion · Acquired 1,940,043 · Balance 1,940,043 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Row 3 · 2021-06-28 · Purchase · Acquired 157,895 · Balance 2,097,938 F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-28 · Conversion · Disposed 20,004,280 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-28 · Conversion · Disposed 3,000,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-28 · Conversion · Disposed 4,150,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-28 · Conversion · Disposed 2,699,328 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2020 Filed Oct 13, 2020 23:48 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 7,774 | $33.25 | $258,461.40 |
DisclosureSEC source: 0000899243-20-028072 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,748,886 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 23:48 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,122 | $33.68 | $37,789.63 |
DisclosureSEC source: 0000899243-20-028072 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 999,449 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.51 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 23:48 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,027 | $33.25 | $34,144.57 |
DisclosureSEC source: 0000899243-20-028072 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000,571 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 16 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,178 F22 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I GP LP. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 4,131 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 15 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F21 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners. F17 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 14 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,131 F20 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel. F17 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 57,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 13 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 486,597 F18 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F19 · ownership.nature: Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,033 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,033 F16 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I. F17 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 192,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,631,864 F14 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F15 · ownership.nature: Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 22 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,729 F13 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP-GP. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F12 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members. F11 · ownership.nature: Shares held by Versant Vantage I GP-GP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 588 F10 · kind: Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP. F11 · ownership.nature: Shares held by Versant Vantage I GP-GP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 593 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners. F8 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 593 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 593 F7 · kind: Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I. F8 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 39,608 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,001,598 F6 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, to its partners, pursuant to a Rule 10b5-1 distribution plan. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 24,590 | $33.56 | $825,154.34 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,756,660 F1 · kind: The sale of these shares were affected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,246 | $33.56 | $108,924.40 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,041,206 F1 · kind: The sale of these shares were affected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 15,980 | $33.26 | $531,477.22 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,781,250 F1 · kind: The sale of these shares were affected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 23:14 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,110 | $33.26 | $70,176.28 |
DisclosureSEC source: 0000899243-20-027853 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,044,452 F1 · kind: The sale of these shares were affected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 22:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 14,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,171 F8 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 22:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 1,948 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,355 F6 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F7 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 22:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 84,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV, to its members. F4 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 22:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 84,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,544 F3 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV. F4 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 22:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 328,324 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,746,493 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 00:10 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,035 | $86.87 | $263,635.88 |
DisclosureSEC source: 0000899243-20-025969 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 518,190 F1 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $86.85 to $86.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 18 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,707 F27 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I GP LP. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 4,131 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 17 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F26 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners. F22 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 16 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,131 F25 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel. F22 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 57,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 15 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 544,021 F23 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F24 · ownership.nature: Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,033 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 14 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,033 F21 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I. F22 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 192,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 13 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,824,440 F19 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F20 · ownership.nature: Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,258 F18 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP-GP. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,177 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members. F16 · ownership.nature: Shares held by Versant Vantage I GP-GP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,177 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,177 F15 · kind: Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP. F16 · ownership.nature: Shares held by Versant Vantage I GP-GP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F14 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners. F13 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,187 F12 · kind: Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I. F13 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 79,216 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,046,562 F10 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F11 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 2,289 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,216 F9 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP-GP. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,901 F6 · kind: Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,000 F3 · kind: Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 23:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025830 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,797,230 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI"), to its partners. F2 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 8,965 | $86.98 | $779,777.49 |
DisclosureSEC source: 0000899243-20-025722 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 521,225 F1 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $86.85 to $87.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 14, 2020 Filed Sep 17, 2020 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,155 | $84.89 | $98,045.29 |
DisclosureSEC source: 0000899243-20-025417 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 530,190 F1 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $84.85 to $84.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 8,684 | $85.90 | $745,930.42 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 531,345 F9 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F13 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (13) to this Form 4. F12 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 14,161 | $85.03 | $1,204,065.93 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 540,029 F9 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $84.50 to $85.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (11) to this Form 4. F12 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 09, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 7,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,391 F8 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of securities as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV IV. Read SEC document |
| September 09, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 42,272 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F7 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members. F6 · ownership.nature: These securities are held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 09, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 42,272 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 42,272 F5 · kind: Represents a change in the form of ownership of VV IV, by virtue of the receipt of securities as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC IV. F6 · ownership.nature: These securities are held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.